Key Takeaways
- A quarter hit by geopolitics, not demand: Revenue and margins fell sharply as the Ukraine war drove a 3x surge in European energy costs, spiked wool grease prices, and inflated logistics, while FX losses added a one-off sting. Management calls the pipeline strong and expects cost pass-through to restore margins over the next two quarters.
- Carbogen Amcis development engine is full: A $96 million backlog of development work provides more than 12 months of visibility, and the economics of the R&D phase carry better margins than commercial supply.
- The BV business cratered on a tough comp and input costs: Revenue fell 46% YoY against a quarter where one customer took 38% of annual supply, while wool grease prices and energy costs crushed margins to 19.3%. Normalization is expected through the year.
- A new French fill-and-finish facility opens a formulations foray: The greenfield project, kept competitive through negotiated energy and land deals, targets a Q1 FY24 opening and a first project launch by end of Q1 CY23, adding a new revenue stream from next financial year.
- What to watch next quarter: Whether wool grease and energy costs actually ease, the pace of selling-price increases to restore Dutch margins toward 25–30%, and any update on the Bavla EDQM reinspection timeline.
The Geopolitical Cost Shock
- Energy costs hit Europe hardest: Power and fuel costs in the Netherlands rose roughly 3–3.5x YoY, driven by the Russia-Ukraine war driving up European gas prices, making it the single largest margin drag in the Dutch business.
- Wool grease prices spiked on supply disruption: The primary raw material for cholesterol and Vitamin D analogs jumped after another company sourced too much from the supplier, compressing BV margins from a ~30% norm to 19.3%. Prices are seen coming off and expected to normalize as the year progresses.
- Logistics costs stayed elevated: High freight and logistics costs persisted at levels similar to Q4 FY22, affecting all businesses and adding to the geopolitical margin squeeze.
- Cost pass-through is coming, but with a lag: Management expects most cost increases to be passed to customers, but already accepted orders and competitive pressure create a time lag of at least two quarters before the full effect is visible.
- A one-off FX loss amplified the pain: A ₹9 crore realized FX loss, largely from a large bullet loan repayment combined with USD-INR movement, hit other expenses; no similar large repayment is expected in the next nine months.
Dalal: "While we do expect that most of this cost would be passed on to the customers in the foreseeable future, there is definitely a time lag due to the already accepted orders, as well as the competition."
Carbogen Amcis: The Development Backlog Is the Story
- Development pipeline hit $96 million: The backlog of development work yet to start gives more than a year of forward visibility, a level management calls "very, very comfortable."
- R&D-phase economics are better than commercial: Margins on development work exceed those on commercial supply, where big pricing pressure kicks in, so products staying in Phase III are not a negative for profitability.
- Commercial supply delayed, not lost: Certain commercial product supplies were delayed from Q1 and are shipping in the current quarter, with a higher amount of commercial sales expected in the remainder quarters.
- Three molecules could reach market soon: Three projects are very likely to come to market in the next 12–15 months if customer plans hold, consistent with the historical pattern of 2–3 molecules reaching market from a pipeline of 15–20.
- No Indian competition in NCE: Management stated it faces no competition from any Indian player for the NCE business that comes to Carbogen Amcis, a structural moat around the Swiss CDMO's positioning.
- Large-scale manufacturing to shift east: Large-scale manufacturing is not expected out of Swiss or European sites; the plan is to utilize China and India sites for scale-up, playing synergies between the Swiss entity and the India-China business.
Villemagne: "We actually do sometimes more money into the development phase because there is a lot to do than a commercial side. In the commercial side, then we start to have a big pressure on pricing. ... So, we do more margins on the R&D phase."
BV Business: A Perfect Storm, Not a Structural Break
- Revenue comp was exceptionally tough: The 46% YoY revenue decline reflects Q1 FY22 having booked 38% of annual cholesterol revenue from one customer in a single quarter, not a demand collapse. Revenue is expected to ramp through the remainder of the year.
- Wool grease was the margin killer: The primary raw material price increase, combined with 3–3.5x power and fuel costs in the Netherlands, drove margins down to 19.3% from a historical ~30%.
- Recovery levers are in motion: Wool grease prices are already seen coming off, the sales team is working to increase selling prices for both cholesterol and Vitamin D analog segments, and raw material costs are expected to pull off through the remainder of the year.
- 30% margin may take a few quarters: Management does not expect to hit the 30% margin in the current quarter but sees it as achievable in later quarters as cost normalization and price increases take hold.
Villemagne: "I fully understand the disappointment and we are the first to be disappointed in that matter. We really are looking to get back on track earlier, but of course the significant events and situation in Ukraine has affected a lot of the raw materials for instance on the cost of energy which affected our revenues."
French Fill-and-Finish Facility: The Next Growth Leg
- A formulations foray with competitive advantage: The greenfield project marks Dishman's entry into fill-and-finish, with management keeping customer control over construction and negotiating favorable energy and land deals to ensure high competitiveness and a short return on investment.
- Timeline points to FY24 revenue start: The facility opening is expected during Q1 2024, with the first project launch targeted by end of Q1'23; a regulatory dossier has been filed with French authorities, with a response expected within six months.
- Funding is in place: About 50% of the CHF 10 crore funding raised is allocated to the French project, with the remainder going to Swiss CAPEX and SAP implementation across Carbogen Amcis; debt is being taken now for front-ended CAPEX and will be paid off from future cash flows.
Villemagne: "We successfully conclude some great negotiations from the petroleum point of view and we kept our customer control over the construction of that inside, which is going to give us a significant competitive advantage in front of some competitors that are building the same kind of facility."
India Business & Regulatory Recovery
- India CRAMS getting back on track: Revenue at Bavla and Naroda sites recovered quite a bit, with Bavla CRAMS margins expected to ramp up on significant expected future revenues; the APIs and intermediates side reported positive EBITDA of ~10%.
- Bavla EDQM reinspection on the horizon: Technical changes and improvements have been carried out, and the company expects to be completely ready by October 2022 to inform the authority and request reinspection; management feels "pretty confident" of passing.
- Customer audits cleared: The company successfully passed many customer audits, allowing resumption of production of almost all CRAMS products for customers, a key operational milestone.
- Focus generics and Quartz performed well: Both revenue and margins were strong in Q1, with expectations of continued ramp-up and profit contribution.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | At least 10%, higher side 12–14% | FY23 full year |
| EBITDA margin | Around 20% for the full year | FY23 full year |
| Dutch business margin recovery | Margins to reach 25–30% | Remaining three quarters of FY23 |
| Cost pass-through visibility | Full effect of pass-through to customers visible | At least two quarters |
| French facility opening | Facility opens, new revenue stream begins | Q1 FY24 |
| French facility first project | First project launch from new facility | End of Q1 CY23 |
| Bavla EDQM reinspection readiness | Ready to inform authority for reinspection | October 2022 |
| India business normalcy | 70% normalcy achieved | FY23 |
| Molecule commercialization | 3 projects very likely to come to market | Next 12–15 months |
| No major FX loan loss repeat | No large bullet repayments due | Next nine months |
Key Metrics
| Metric | Q1 FY23 |
|---|---|
| Consolidated revenue from operations | ₹541 cr |
| Gross contribution | ~82%, management aims for ~20% cost |
| Reported EBITDA | ₹88 cr |
| Normalized EBITDA | ~₹90 cr, adjusting for ~₹2 cr FX interpretation impact |
| Employee expenses | ₹256 cr, in line with Q4 FY22, expected to remain in this range for remainder FY23 |
| Other expenses | ₹104 cr, includes FX loss of ~₹9 cr |
| Finance cost | ₹19 cr, includes FOREX loss of ₹3 cr |
| Dishman India APIs and intermediates revenue | ₹62 cr, ~92% YoY growth from ₹32 cr in Q1 FY22 |
| Focus generics revenue | ₹51 cr, 7% growth |
| Carbogen Amcis CRAMS revenue | ₹363 cr, ~3% YoY growth |
| Carbogen Amcis BV (cholesterol and Vitamin D analogs) revenue | ₹63 cr, 46% YoY drop; last year Q1 had a single customer supply comprising ~38% of annual revenue |
| India APIs and intermediates EBITDA margin | ~10% |
| Carbogen Amcis CRAMS EBITDA margin | 19.4% |
| Cholesterol and Vitamin D analog business EBITDA margin | 19.3%, historically ~30%; drop due to higher wool grease prices and energy costs |
| Development orders yet to start | $96 million, providing visibility for next 12 months |
| Phase-III molecules in CRAMS portfolio | 17 molecules |
| Molecules moved from development to commercialization in last three years | 6 to 7 molecules |
| Molecules very likely to come to market in next 12 to 15 months | 3 projects |
| Total molecules across different phases of development | ~450 molecules |
| FY23 revenue growth guidance | At least 10%, on the higher side 12% to 14% |
| FY23 EBITDA margin guidance | Around 20% for the full year |
| FX exposures hedged for remainder of FY23 | 60% to 70% |
| Energy cost differential in Netherlands vs Q1 FY22 | ~3x to 3.5x |